ClinicalTrials.gg
CompletedNCT04537793Updated Jun 28, 2023Results posted

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 22 sites in 5 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
15th of 23
83 · median 120
Started
2020
with 4 others
Phase 3
19 of 23
none open now
Registered
11th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 15th largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 11th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects 2 through 5 years of age.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Homozygous for the F508del mutation or heterozygous for F508del and a minimal function (MF) mutation (F/F or F/MF genotypes)

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Solid organ or hematological transplantation

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Part A: ELX/TEZ/IVA

    Participants weighing greater than or equal to (\>=)14 kilograms (kg) at screening received elexacaftor (ELX) 100 milligrams (mg) once daily (qd)/tezacaftor (TEZ) 50 mg qd/ivacaftor (IVA) 75 mg every 12 hours (q12h) in the treatment period for 15 days.

    Drug: ELX/TEZ/IVA · Drug: IVA

  • Experimental
    Part B: ELX/TEZ/IVA

    Participants weighing (\>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (\>=)10 kg to less than (\<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed dose combination granules for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Granules for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites

    Time frame: From Day 1 through Day 15

  2. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 43

  3. Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 28

Secondary outcomes

  1. Part B: Observed Pre-dose Plasma Concentration (Ctrough) of ELX,TEZ,IVA and Relevant Metabolites

    Time frame: From Day 1 through Week 16

  2. Part B: Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Week 24

  3. Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)

    The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

    Time frame: From Baseline through Week 24

07

Results

Posted Jun 28, 2023

Participant flow

The study was conducted in 2 parts, Part A and Part B. The Participant flow was planned to be presented for the overall treatment arms (i.e. Part A and Part B), irrespective of weight-based dose regimen.

Part A (15 Days)
Participant flow — Part A (15 Days)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started180
Completed180
Not completed00
Part B (24 Weeks)
Participant flow — Part B (24 Weeks)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started075
Completed074
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryPart A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites
Time frame:
From Day 1 through Day 15
Reported as:
Mean · micrograms per milliliter (mcg/ml)
Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites
micrograms per milliliter (mcg/ml)Part A: ELX/TEZ/IVA
Day 1: ELX0.00 ± 0.00
Day 8: ELX3.44 ± 2.09
Day 15: ELX3.69 ± 2.11
Day 1: ELX-M230.00 ± 0.00
Day 8: ELX-M232.39 ± 1.65
Day 15: ELX-M232.47 ± 1.65
Day 1: TEZ0.00 ± 0.00
Day 8: TEZ1.86 ± 1.07
Day 15: TEZ1.85 ± 1.10
Day 1: TEZ-M10.00 ± 0.00
Day 8: TEZ-M16.42 ± 1.42
Day 15: TEZ-M17.68 ± 1.52
Day 1: IVA0.00 ± 0.00
Day 8: IVA0.702 ± 0.503
Day 15: IVA0.746 ± 0.526
Day 1: IVA-M10.00 ± 0.00
Day 8: IVA-M11.78 ± 0.990
Day 15: IVA-M11.91 ± 0.990
PrimaryPart A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 up to Day 43
Reported as:
Number · participants
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart A: ELX/TEZ/IVA
Participants with TEAEs15
Participants with SAEs0
PrimaryPart B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 up to Week 28
Reported as:
Number · participants
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart B: ELX/TEZ/IVA
Participants with TEAEs74
Participants with SAEs2
SecondaryPart B: Observed Pre-dose Plasma Concentration (Ctrough) of ELX,TEZ,IVA and Relevant Metabolites
Time frame:
From Day 1 through Week 16
Reported as:
Mean · micrograms per milliliter (mcg/ml)
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of ELX,TEZ,IVA and Relevant Metabolites
micrograms per milliliter (mcg/ml)Part B: ELX/TEZ/IVA (≥10 kg to <14 kg)Part B: ELX/TEZ/IVA (≥14 kg)
Day 15: ELX2.91 ± 1.383.87 ± 2.75
Week 4: ELX3.13 ± 1.903.56 ± 2.19
Week 12: ELX2.48 ± 1.653.49 ± 2.22
Week 16: ELX3.01 ± 1.113.18 ± 2.19
Day 15: ELX-M231.85 ± 1.122.33 ± 1.87
Week 4: ELX-M232.32 ± 2.012.22 ± 1.66
Week 12: ELX-M231.48 ± 1.272.17 ± 1.69
Week 16: ELX-M231.73 ± 0.8281.94 ± 1.58
Day 15: TEZ1.73 ± 0.6662.14 ± 1.72
Week 4: TEZ1.62 ± 0.7161.79 ± 0.947
Week 12: TEZ1.60 ± 0.9511.76 ± 1.10
Week 16: TEZ1.52 ± 0.7011.80 ± 1.42
Day 15: TEZ-M17.07 ± 1.087.07 ± 2.11
Week 4: TEZ-M16.80 ± 1.647.09 ± 2.18
Week 12: TEZ-M17.06 ± 2.377.18 ± 2.38
Week 16: TEZ-M16.88 ± 1.946.95 ± 2.77
Day 15: IVA0.549 ± 0.3730.661 ± 0.552
Week 4: IVA0.535 ± 0.4020.594 ± 0.405
Week 12: IVA0.383 ± 0.2030.530 ± 0.474
Week 16: IVA0.483 ± 0.3470.580 ± 0.511
Day 15: IVA-M11.47 ± 0.9691.67 ± 0.961
Week 4: IVA-M11.64 ± 1.291.52 ± 0.737
Week 12: IVA-M11.19 ± 0.6021.45 ± 0.907
Week 16: IVA-M11.24 ± 0.6731.51 ± 0.911
SecondaryPart B: Absolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part B: Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)Part B: ELX/TEZ/IVA
Part B: Absolute Change in Sweat Chloride (SwCl)-57.9 (-61.3 to -54.6)
SecondaryPart B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)

The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · index
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)
indexPart B: ELX/TEZ/IVA
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)-0.83 (-1.01 to -0.66)

Adverse events

Collected over Day 1 Through Safety Follow-up Visit (up to Day 43 for Part A, up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: ELX/TEZ/IVA0/18 (0%)0/18 (0%)15/18 (83.3%)
Part B: ELX/TEZ/IVA0/75 (0%)2/75 (2.7%)71/75 (94.7%)
Most frequent serious events
Most frequent serious events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Anal incontinenceGastrointestinal disorders0/181/75
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/181/75
Abnormal behaviourPsychiatric disorders0/181/75
Urinary incontinenceRenal and urinary disorders0/181/75
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders4/1846/75
PyrexiaGeneral disorders1/1826/75
RhinorrhoeaRespiratory, thoracic and mediastinal disorders3/1825/75
VomitingGastrointestinal disorders0/1821/75
COVID-19Infections and infestations0/1814/75
Nasal congestionRespiratory, thoracic and mediastinal disorders0/1813/75
Alanine aminotransferase increasedInvestigations3/188/75
RashSkin and subcutaneous tissue disorders2/1812/75
Upper respiratory tract infectionInfections and infestations1/1811/75
Decreased appetiteMetabolism and nutrition disorders0/189/75

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Categorical
Age, Categorical(Participants)ELX/TEZ/IVA
Part A — <=18 years18
Part A — Between 18 and 65 years0
Part A — >=65 years0
Part B — <=18 years75
Part B — Between 18 and 65 years0
Part B — >=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Part A — Female11
Part A — Male7
Part B — Female41
Part B — Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Part A — Hispanic or Latino0
Part A — Not Hispanic or Latino18
Part A — Not collected per local regulations0
Part B — Hispanic or Latino6
Part B — Not Hispanic or Latino63
Part B — Not collected per local regulations6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Part A — White18
Part A — Black or African American0
Part A — Not collected per local regulations0
Part B — White68
Part B — Black or African American1
Part B — Not collected per local regulations6
08

Study locations

22 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine / St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • NC TraCS Institute - CTRC University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, VIC, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie
    Essen, Germany
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2022, 18 months.

Results were first posted in Jun 2023, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 18 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Sep 3, 2020
StartActual
Nov 19, 2020
Primary completionActual
Jun 3, 2022
CompletionActual
Jun 3, 2022
Results first posted
Jun 28, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04537793
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Nov 19, 2020
Primary completion
Jun 3, 2022
Completion
Jun 3, 2022
Results posted
Jun 28, 2023
Last update
Jun 28, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion